The US Food and Drug Administration recently warned about the risks associated with using robotic devices during mastectomies and other cancer surgeries. The agency is cautioning that these devices may increase health safety risks, and they could even result in poor surgery outcomes for
patients.
The new report is based on the agency’s review of recent studies that suggest that robotic surgical devices may not be entirely safe and effective. The warning says that the data on the risks of these robotic surgery tools, when used in cancer procures, is very limited. The agency also emphasized that it cannot verify how effective these tools actually are.
Recent studies have been questioning the effectiveness of using robotic tools in cancer procedures. For example, a recent study in the New England Journal of Medicine linked the use of these devices in cervical cancer surgeries with a lower disease-free survival rate, as well as an overall post-operation survival rate, when compared with traditional surgery techniques.
Robotically-assisted surgery has been on the rise in recent years, as new technology has emerged to assist surgeons in a variety of procedures. The robots make tiny and very precise incisions—more precise than can typically be made by a surgeon’s hand—which can aid in the patient’s
recovery, and help reduce pain, scarring and the risk of infection. The FDA confirms, too, that patient recovery time is quicker when using robotic surgery devices, in comparison to traditional surgical techniques.
But the FDA says it’s worried that surgeons, health care providers and patients may not be fully aware that the safety and effectiveness of these devices in mastectomy procedures has not been established. Nor is there sufficient data regarding the safety and effectiveness in using robotic devices in surgeries intended to treat or prevent cancer. The agency cited peer-reviewed journal studies, including the study in the New England Journal of Medicine, that show that the minimally invasive robotic surgery actually had a lower survival rate than traditional, open-abdomen surgery in hysterectomy procedures to treat patients with cervical cancer.
Because of the lack of data and the studies suggesting lower survival rates with surgeries using these devices, the FDA has refused to grant marketing clearance for any robotically-assisted medical devices for the prevention or treatment of cancer—and in particular, breast cancer. Additionally, any robotic surgical devices sold in the United States must include a warning label that states that cancer treatment outcomes when using this device have not been fully evaluated by the FDA.
In issuing its warning, the FDA emphasized that it takes women’s health issues very seriously. Therefore, the agency believes that this safety warning communication was necessary to help doctors and patients understand that these devices have not been fully vetted by the medical community. The agency is emphasizing that more studies are needed to collect more data on patient survival rate, patient post-operative health, and the risks and benefits associated with these devices.
In the meantime, the agency is encouraging patients, health care providers, and patient caregivers to discuss all the risks and benefits associated with these robotic devices before making a decision regarding their surgery procedure. Patients should also talk about alternatives to robotic operations with their doctors before making a decision. Finally, before committing to a robotically-assisted cancer surgery, patients should question their surgeon about his or her level of training, experience in robotic surgery, and outcomes of the patients he or she has treated with robotically-assisted surgery.